<DOC>
	<DOCNO>NCT01033240</DOCNO>
	<brief_summary>The purpose study determine safety efficacy CS-1008 combination sorafenib sorafenib alone treat liver cancer . Approximately 160 participant take part study approximately 22 site ( 4 US , 8 Japan , 10 Asia ) .</brief_summary>
	<brief_title>CS1008- Combination With Sorafenib Compared Sorafenib Alone Subjects With Advanced Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm HCC clinical diagnosis HCC follow criterion meet : History chronic hepatitis and/or cirrhosis liver ; Typical feature HCC demonstrate dynamic imaging study , threephase compute tomography ( CT ) ; AND AFP level &gt; 200 ng/mL Advanced diseases Extrahepatic metastasis , OR Locally advance disease amendable surgical resection locoregional therapy include transhepatic arterial ( chemo ) embolization ( TACE TAE ) local ablative therapy Measurable disease base RECIST criterion ( version 1.0 ) least 1 untreated target lesion measure 1 dimension At least 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ChildPugh class A Life expectancy least 12 week Adequate organ bone marrow function assess clinical laboratory evaluation : Hemoglobin ≥ 8.5 g/dL ( transfusion and/or growth factor support allow ) Absolute neutrophil count ( ANC ) ? ? ? 1.0 x 109/L Platelet count ≥ 75 x 109/L Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) creatinine clearance &gt; 40 mL/min AST alkaline phosphatase ? ? ? 5.0 x ULN Total bilirubin ≤ 1.5 x ULN Serum amylase lipase ≤ 1.5 x ULN Women childbearing potential must willing consent use effective contraception ( eg , abstinence , hormonal contraceptive , bilateral tubal ligation , barrier spermicide , intrauterine device ) treatment 3 month thereafter . Men partner woman childbearing potential must willing consent use effective contraception ( eg , vasectomy barrier spermicide ) treatment 3 month thereafter All female subject childbearing potential must negative pregnancy test ( serum urine ) result Subjects must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) must sign date IRB/IEC approve ICF performance study specific procedure test Subjects must willing able comply schedule visit , treatment plan , laboratory test , study procedure Any prior systemic therapy HCC , include systemic chemotherapy ( prior exposure chemotherapy TACE allow ) , immunotherapy , sorafenib Raf kinase inhibitor , VEGF/VEGFRinhibitors , epidermal growth factor receptor inhibitor mTOR inhibitor Radiotherapy major surgical procedure within 4 week screening/baseline visit minor surgical procedure ( eg , core biopsy fine needle aspiration ) within 2 week screening/baseline visit Anticipation need RT major surgical procedure study Any investigational agent within 4 week screening/baseline visit History follow condition within 6 month screening/baseline visit : Myocardial infarction significant impairment cardiac function ( eg , ejection fraction ≤ 30 % ) Severe/unstable angina pectoris New York Heart Association ( NYHA ) class III IV congestive heart failure ( Section 17.2 ) Clinically significant pulmonary disease ( eg , severe chronic obstructive pulmonary disease asthma ) Clinically active brain metastasis ( define untreated , symptomatic require steroid anticonvulsant medication control associate symptom ) , uncontrolled seizure disorder ; spinal cord compression ; carcinomatous meningitis . Subjects treat brain metastasis include study recover acute , toxic effect radiotherapy . A minimum 15 day must elapse end RT screening/baseline visit History organ transplantation Clinically significant , severe , active infection require IV antibiotic Known history human immunodeficiency virus ( HIV ) infection History prior sensitivity reaction component CS1008 sorafenib formulation History second malignancy , exception situ cervical cancer adequately treat basal cell squamous cell carcinoma skin Pregnant breast feed Serious intercurrent medical illness , opinion Investigator , would impair subject 's ability provide inform consent unacceptably reduce safety propose treatment Clinically significant ( National Cancer Institute Common Terminology Criteria Adverse Events [ NCI CTCAE ] grade ≥ 3 ) gastrointestinal bleed past 12 month current active gastrointestinal bleeding Presence esophageal varix risk bleeding , large esophageal/gastric varix red sign , active peptic ulcer without expose vessel risk bleeding ( document endoscopy ) History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>